



07-28-03

1642

Docket No. 3828-4000US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JUL 3 JUL 25 2003

TECH CENTER 1600/2000

Applicant(s): Cohava GELBER

Group Art Unit: 1642

Serial No.: 09/995,522

Examiner:

Larry R. Helms, Ph.D.

Filed: November 28, 2001

For: **MYELOMA CELL AND OVARIAN CANCER CELL SURFCE
GLYCOPROTEIN, ANTIBODIES THERETO, AND USES THEREOF**

EXPRESS MAIL CERTIFICATE

Mail Stop Non-Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Express Mail Label No.: EV 357 802 435 US

Date of Deposit: July 25, 2003


I hereby certify that the following attached paper(s) and/or fee

1. Amendment And Response to Restriction Requirement;
2. Amendment Fee Transmittal; and
3. Return receipt postcard

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Ron London

(Typed or printed name of person mailing paper(s) and/or fee)



(Signature of person mailing paper(s) and/or fee)

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154-0053
(212) 758-4800 Telephone
(212) 751-6849 Facsimile



Docket No. 3828-400091

RECEIVED
JUL 31 2003

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Cohava GELBER

Group Art Unit: 1642

Serial No.: 09/995,522

Examiner: Larry R. Helms, Ph.D.

Filed: November 28, 2001

For: MYELOMA CELL AND OVARIAN CANCER CELL SURFACE
GLYCOPROTEIN, ANTIBODIES THERETO, AND USES THEREOFAMENDMENT FEE TRANSMITTAL

Mail Stop Non-Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith is an Amendment for the above-identified application.

No additional fee is required.
 The additional fee has been calculated as shown below:

CLAIMS AS AMENDED

	Claims Remaining After Amendment	Highest No. Covered by Previous Payments	Extra	Rate	Additional Fee
Total Claims*	-			\$18.00/ \$9.00	\$
Independent Claims	-			\$84.00/ \$42.00	\$
Multiple Dependent Claims	(If claims added by amendment include Multiple Dependent Claim(s) and there was no Multiple Dependent Claim(s) in application before amendment add \$280.00 to additional fee (\$140.00 for small entity).)				
TOTAL					\$

*Includes all independent and single dependent claims and all claims referred to in multiple dependent claims. See 37 C.F.R. §1.75(c).

Small entity status is or has been claimed.
Reduced Fees Under 37 C.F.R. §1.9(f) paid herewith \$_____

_____ Pages Sequence Listing

_____ Computer disk(s) containing substitute Sequence Listing

Statement under 37 C.F.R. §1.825(b) that the computer and paper copies of the substitute Sequence Listing are the same.


A check in the amount of \$_____ to cover the filing fee is attached.

Charge fee to Deposit Account No. 13-4500, Order No. _____. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

The Commissioner is hereby authorized to charge any additional fees which may be required for filing this amendment, including all fees pursuant to 37 CFR §1.17 for its timely consideration, or credit any overpayment to Deposit Account No. 13-4500, Order No. 3828-4000US1. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,
MORGAN & FINNEGAN, L.L.P.

Dated: July 25, 2003

By: 
Paula K. Wittmayer
Registration No. 53,785

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154-0053
(212) 758-4800 Telephone
(212) 751-6849 Facsimile



Andy B
Docket No.: 3858-4000US1

JUL 30 2003

RECEIVED

PATENT
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Cohava GELBER
Serial No. : 09/995,522
Filed : November 28, 2001
Group Art Unit : 1642
Examiner : Larry R. Helms, Ph.D.
For : **Myeloma Cell And Ovarian Cancer Cell Surface Glycoprotein, Antibodies Thereto, and Uses Thereof**

Mail Stop Non Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

This is in response to the Restriction/Election Requirement, dated June 25, 2003, in the above-identified patent application. Entry and consideration of this response are respectfully requested.

Additions to the claims are reflected in the Listing of the Claims which begins on page 2 of this paper.

Remarks begin on page 14 of this paper.